Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

A number of other equities research analysts have also recently commented on the company. Northland Securities reiterated a “market perform” rating and set a $2.00 target price on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Oncternal Therapeutics currently has a consensus rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Stock Performance

Shares of Oncternal Therapeutics stock opened at $0.53 on Friday. The business’s fifty day simple moving average is $0.98 and its 200 day simple moving average is $3.40. Oncternal Therapeutics has a 12 month low of $0.53 and a 12 month high of $13.14. The firm has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.